A urea-soluble extract of cyst-rich material from rat lung heavily infected with Pneumocystis carinii was evaluated in an enzyme-linked immunosorption assay for antibody in 461 human sera. The highest level of reactivity occurred in sera submitted for serodiagnosis from proved or highly suspect cases. However, the range of reactivities in these groups, many of whom were on immunosuppressive therapy, was very wide. A more restricted lower range of reactivity was observed in both hospital-family contacts and healthy Serum Bank donors. Because of the overlap in levels of reactivity between the pneumocystosis and control groups, no concise cutoff value to separate infected from noninfected individuals could be made. Specificity of the reactions was shown by absorption of patients' and control sera with uninfected and P. carinii-infected human and rat lung tissue. The data support the concept that P. carinii is highly prevalent as a latent agent in the general population and is provoked to cause clinically manifest disease in the compromised host. Detection of circulating antigen appeared to be specific and possibly a useful adjunct to diagnosis, as 10 of the 14 proved or highly suspect patients with antigenemia did not have measurable antibody to P. carinii.
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Definitive diagnosis of pneumocystic pneumonitis is made by demonstration of Pneuimocystis carinii cysts in lung tissue (6) . The hazards for patients of the various procedures by which such tissue can be obtained are significant at all times and more so in patients with respiratory distress. Serology was therefore investigated as an adjunct to diagnosis. The first report of using complement fixation (CF) for serodiagnosis in pneumocystosis was made in 1955 (25) . The CF test was sensitive and detected 75 to 95% of cases of interstitial plasma-cell pneumonitis due to P. carinii in children (6) . Some, but not all, studies showed antibody in up to 30% of healthy individuals. Reactivity in a microcomplement fixation test, however, did not correlate with histologically demonstrable P. carinii in the lungs (12) . In an Iranian orphanage the CF test was negative in infants during the crisis of acute infection with P. carinii (2) . Antibodies were detectable 1 to 2 months after the episode of pneumonitis.
In contrast to the high sensitivity of the CF test in central Europe for interstitial plasma-cell pneumonia due to infection with P. carinii in young infants, the test had low sensitivity in the United States where pneumocystosis patients were on immunosuppressive therapy (17, 21) for underlying malignancies or had primary immune deficiencies.
The only other published report of a serodiagnostic test for pneumocystosis using a soluble antigen was that by Benex (1) . She found that a latex agglutination test was insensitive and detected only approximately 35% of infected humans or experimental animals.
More recent serodiagnostic studies on pneumocystosis have used indirect immunofluorescence (IIF) to detect antibody. Cysts separated from infected human lung were dried onto slides for antigen (17) . IIF was more sensitive than CF, as 44% of sera from probable pneumocystosis patients was positive by IIF and only 22% by CF (18) . In addition, IIF eliminated the problem of anti-complementary sera. The IIF, however, has been found by some investigators to have limitations as a serodiagnostic tool for pneumocystosis in immunosuppressed patients because of lack of sensitivity (7, 23) and because antibodies were detectable in appreciable numbers of healthy controls (11, 14, 19) .
The enzyme-linked immunosorbent assay (ELISA) has found wide application as a sensitive quantitative serodiagnostic procedure for many infectious diseases, including protozoal and helminthic infections. We now report on our evaluation of ELISA as a serodiagnostic tool for human infection with P. carinii. The antigen used was a urea-solubilized extract of P. carinii cysts separated from infected rat lungs. Specificity of the reactivity was confirmed by testing sera with antigen from normal rat lung and by absorbing reactive sera with infected and normal rat and human lung tissues. We also evaluated and here report on the counterimmunoelectrophoresis (CIE) assay described by Pifer et al. (19) for the demonstration of circulating antigen in patients' sera.
Our results reemphasize some of the difficulties encountered in attempting to measure antibody response in immunosuppressed patients. The concept that P. carinii infection may occur without severe, progressive clinical symptoms is supported by our findings.
MATERIALS AND METHODS
Human sera. The following groups of sera were studied: (i) 88 parasitologically proved and 38 clinically highly suspect cases of pneumonitis due to infection with P. carinii. Many of these patients were known to be on immunotherapy. However, the duration of illness and of therapy of these patients and the treatment status of the other patients in these groups were not known. The other groups were: (ii) 153 healthy hospital or family contacts associated with cases in the United States (these sera were submitted to the Parasitology Division, Centers for Disease Control [CDC] for special studies on the serology of pneumocystosis); (iii) 21 sera serologically positive for Histoplasma capsulatum (provided by L. Kaufman, CDC); (iv) paired sera from 28 cases of suspected infection with Legionella pneumophila (provided by H. Wilkinson, CDC); (v) 105 healthy U.S. adults (sera were obtained from the CDC Serum Bank).
Rabbit sera. The preparation of the rabbit anti-P. carinii serum for detecting antigenemia has been previously described in detail (10) . Two rabbits were immunized with an HCl extract of P. carinii organisms in Freund adjuvant. The antisera were absorbed with insolubilized normal rat globulin.
For specificity studies, two rabbits were immunized with a Hanks balanced salt solution (HBSS) extract of P. carinii cyst-rich material as previously described (10) . The preparation of one rabbit serum against an extract of noi-mal human lung and two rabbit antinormal rat lung sera has been previously described (7) . The animals were immunized with phosphate-buffered saline (PBS) extracts of normal lung tissues emulsified in Freund adjuvant.
P. carinii antigens. The preparation of P. carinii antigens has been described in detail (10) . Briefly, P. carinii infection was induced in rats by the administration of corticosteroids. The organisms were concentrated by enzyme digestion and gradient centrifugation to yield a cyst-rich fraction that was extracted with HBSS, 8 M urea, or HCl. In addition, a small amount of infected human lung that had been stored at -50°C for 10 years was processed to yield a urea antigen by applying the same method as used for processing infected rat lung.
Normal tissue antigens. Portions of lung obtained at autopsies of two individuals whose cause of death was not related to lung problems were processed by using the above technique to yield urea extracts of normal human lung. A urea extract of normal rat lung was similarly prepared. Impression smears stained by toluidine blue 0 and histological examination with Methenamine-Gomori silver stain failed to show P. carinii cysts in the human tissues and only very rarely showed organisms in the rat lung.
Absorption of sera. After initially stirring chopped infected or normal lung to free the P. carinii organisms (used for antigen production), we chopped portions of particulate lung material even more finely and washed them three times with PBS. The final centrifuging of small portions of these tissues was made in tubes (10 by 75 mm) at 12,000 x g for 2 h. Serum in 0.2-ml amounts was added to approximately 0.2 ml of packed tissue. The mixture was triturated with a glass rod and allowed to stand overnight at 4°C. The absorbed serum was clarified by centrifuging at 12,000 x g for 2 h.
ELISA. The ELISA assay made in our laboratory for pneumocystosis has been fully described (10) . Briefly, urea antigens were bound to polystyrene plates in carbonate buffer, pH 9. CIE. The conditions of the CIE assay used in our laboratory have been described in detail (10) and are the same as those used by L. L. Pifer (19) . The antiserum we prepared against the HCl P. carinii antigen was shown in her laboratory to detect antigenemia in human sera.
RESULTS
The antibody levels of the 461 sera tested in ELISA against the urea P. carinii antigen are shown in Table 1 Fig. 1 , in which the OD490 of 1:64 dilutions of sera are plotted against the numbers of reactors. Somewhat similar curves peaking between OD490 of 0.19 and 0.39 were observed when the reactivities of the parasitologically proved group plus highly suspect patients and healthy Serum Bank donors were plotted separately (Fig. 2) . Analysis of the geometric means and the confidence levels of the means of the six groups of patients listed in Table 1 shows that the clinically highly infected patients had a significantly higher level of reactivity than did the patients serologically positive for H. capsulatum. Overlap in levels of reactivity was observed between all other groups (Table 2).
To investigate the specificity of the reactions observed in ELISA with the urea-extracted P. carinii antigen, we made the following studies: (i) eight reactive human sera were absorbed with normal and infected rat and human lung tissues and tested against the urea-extracted rat P. carinii antigen; (ii) one rabbit anti-normal human lung and two anti-normal rat lung sera were absorbed with normal rat and human lung tissues; (iii) human sera were tested against urea antigens of normal rat lung; and (iv) sera of rabbits immunized against normal lung tissues or against P. carinii antigens were tested against urea-extracted antigens from P. carinii-infected and normal rat and human lung tissue. The effects of the absorptions were evaluated in ELISA. Table 3 shows that infected human and rat lung removed or, in three strongly reactive sera, markedly reduced the reactivities of the sera from proved infections and healthy Serum Bank donors against urea-extracted P. carinii-infected rat lung. Absorption of the same sera with normal human or rat lung tissues resulted in only minor reductions in reactivities. The reactivities of two rabbit anti-normal rat lung sera were completely removed by absorption with normal rat lung but only slightly reduced by absorption with normal human lung (Table 3) .
When we attempted to test the human sera with antigens from infected and normal human lungs, we observed reactivity throughout the plates. The reactivities of the anti-human and anti-rabbit immunoglobulin conjugates against the various antigens alone in routinely sensitized plates are shown in 
but not with rat antigens. Because only a very small amount of P. carinii human lung antigen was available, we did not attempt to absorb the goat anti-human conjugate. The anti-rabbit conjugate reacted with neither rat nor human antigens. Table 5 compares the reactivities of nine human sera (samples of eight of which had been used in the absorption studies shown in Table 3 ) against urea antigens from infected and from normal rat lungs. None of the sera reacted with the control urea antigen from normal rat lung. A further 48 sera that had OD490 .0.40 with the P. carinii antigen all failed to react with the control antigen.
Because of the specificity of the goat antirabbit conjugate, the immunized rabbit sera could be tested against both the rat and human antigens. The data are shown in Table 6 . The anti-normal human lung serum did not react with the rat antigens but reacted equally well with infected or normal human antigens. In contrast, the anti-normal rat lung sera reacted with both rat and human antigens: antiserum 1 showed less cross-reactivity with antigens of human antigen than did antiserum 2.
The rabbits immunized with HBSS or HCl antigens from infected rat lung produced antisera which after absorption with normal rat globulin reacted strongly with urea antigens of P. carinii from infected rat or human lungs but not with normal human lung antigen. All three antisera had low reactivity against normal rat lung (Table 6 ). Circulating antigen as detected by rabbit antisera against HCI antigen of P. carinii was present in 11 and 19%, respectively, of sera from parasitologically proved and highly suspect cases (Table 7) . Of the 14 sera with antigenemia, 10 had very low OD490 (<0.30) in ELISA. The prevalence of antigenemia was only 1% in the healthy Serum Bank donors and slightly higher (5%) in the hospital and (3%) in the family contact group.
The follow-up specimen of one pair of sera from the suspect L. pneumophilia infections had circulating antigen: both of the sera from this patient had OD490 in ELISA of <0. 15 Specific, albeit somewhat less sensitive, reactivity in IIF using isolated human P. carinii cysts was observed in immunosuppressed patients (7, 17, 18) . Kagan and Norman (8) suggested that the increased sensitivity of the test from previously observed levels of 30% (7) (Table 5 ). None of 50 of these human sera which reacted with rat P. carinii antigen reacted with normal rat lung antigen. In contrast, the rabbit anti-normal rat lung sera reacted strongly with this antigen (Table 6 ). Although the ELISA assay described in this paper is of limited use as a diagnostic tool, the data on the high prevalence of antibody in healthy controls agree with two earlier studies (14, 19) , both of which used the IIF assay for detecting antibody. In a study of children with acute lymphatic leukemia (14) , those with P. carinii pneumonitis had higher levels of IgG class antibody detectable by IIF than those without the infection. However, the usefulness of the IIF as a diagnostic aid was limited because prevalence of antibodies in normal children indicated that 100% of children had acquired infection with P. carinii during the first 2 years of life. The IIF antigen in the study was prepared from infected human lung. Tissue homogenates were treated with pronase to free the P. carinii cysts in lung tissue (13) . Absorption data were not shown, but the authors stated that absorption of reactive sera with suspensions of cysts of P. carinii or with uninfected lung tissue or yeasts supported the specificity of the test.
In the second study with which our data on the healthy controls agree, 71% of 31 children with cancer and proved P. carinii pneumonitis had detectable antibody (19) . The incidence of antibody rose to 97% during convalescence. In In our study rat lung was used as the source of P. carinii cyst-rich material for which the antigens were prepared. As a result of the efficacy of chemoprophylaxis and chemotherapy, deaths due to P. carinii infection were very rare at the time we made the study, and infected human lung was not available to us. The degree of cross-reactivity between human and rat P. carinii has not been fully defined, but a recent report (26) indicates that human and rat P. carinii are not antigenically identical. It would, therefore, be important to evaluate urea antigen from infected human lung, should this material become available.
Histological studies of adults at autopsy have shown that 3 to 4% of patients who died without clinical evidence of P. carinii pneumonitis had typical cysts in their lungs (3) . In autopsies on children, investigators in Spain (16) observed a 3% prevalence that they considered evidence of the endemic character of P. carinii in the study area of Barcelona, Spain. Investigators working in Memphis, Tenn. found P. carinii cysts in the lungs of 4% of children with cancer who died of causes other than pneumocystosis (20 (17, 19, 23) give support to this concept; our findings concur.
Several reports have been made on the detection of antigenemia in pneumocystosis patients (15, 19, 24) . In CIE, rabbit antiserum prepared against an HCl-soluble, heat-stable antigen detected antigenemia in 95% of children with P. carinii pneumonitis, in 15% of patients with malignancies but no pneumonitis, and in none of 120 normal children (19) . However, in a study of bone marrow transplant patients, antigen was demonstrable in 47 of 80 marrow recipients without P. carinii pneumonitis. The authors (15) concluded that demonstration of antigenemia was not diagnostic of P. carinii in the absence of clinical or histological indications. In a report on acute pneumonia in infants 2 to 12 weeks of age, 10 had demonstrable antigenemia on admission, but antigenemia was no longer detectable 3 days after initiating trimethoprim-sulfamethoxazole therapy. All 10 infants had anti-P. carinii antibodies of the IgG class when tested 2 to 50 months after discharge (24) .
Detection of circulating antigen appears to be specific but insensitive as a diagnostic aid in our study. However, many of the proven and highly suspect patients were on chemotherapy for P. carinii, which may have accounted for the apparent low sensitivity of the assay. Of particular interest was the finding that 10 of the 14 proved highly suspect patients with antigenemia did not have measurable antibody to P. carinii, suggesting that detection of antigenemia, as assayed in our laboratory, might be a useful adjunct to diagnosis in adults. To evaluate the assay for P. carinii antigenemia in untreated adults suspected of having pneumocystosis would be of considerable interest.
The need for improved serodiagnosis for pneumocystosis is emphasized by the report of the disease in a small number of homosexuals in Los Angeles. An awareness that severe immunosuppression resulting from aggressive chemotherapy for malignancies is not necessarily a prerequisite for susceptibility to clinically manifest infection with P. carinii may result in increased recognition and reporting of the disease. 
ADDENDUM
Two rabbit anti-P. carinii sera used for detection of circulating antigen were absorbed with P. carinii cysts isolated from human lung recently obtained at autopsy. The absorbed antisera no longer reacted with patients' sera in which antigenemia was demonstrable in CIE with the unabsorbed rabbit sera. In a study of 24 homosexual patients with Kaposi's sarcoma and parasitologically proved P. carinii infection, antigenemia was detected in 51%. Antibody response was detected by ELISA in 33% of the same group of patients.
